Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17041147 | ADJUVANT AND VACCINE CONTAINING ADJUVANT | December 2020 | June 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17121065 | COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCE | December 2020 | June 2022 | Allow | 18 | 1 | 0 | No | No |
| 17119548 | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST | December 2020 | April 2022 | Allow | 16 | 1 | 1 | No | No |
| 17112055 | CHIMERIC HEPATITIS D VIRUS ANTIGEN AND HEPATITIS B VIRUS PRE S1 GENES FOR USE ALONE OR IN VACCINES CONTANING HEPATITIS B VIRUS GENES | December 2020 | June 2022 | Allow | 18 | 1 | 0 | Yes | No |
| 17106135 | Virus Purification | November 2020 | February 2022 | Allow | 15 | 0 | 0 | Yes | No |
| 17100671 | TUMOR-SELECTIVE E1A AND E1B MUTANTS | November 2020 | August 2022 | Allow | 21 | 1 | 1 | No | No |
| 17095300 | GENETICALLY MODIFIED RECOMBINANT VACCINIA ANKARA (RMVA) VACCINES OF IMPROVED STABILITY AND METHODS OF PREPARATION THEREOF | November 2020 | March 2024 | Allow | 40 | 1 | 0 | No | No |
| 17093927 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | November 2020 | September 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17089527 | SMALLPOX VACCINE FOR CANCER TREATMENT | November 2020 | November 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 17048714 | SELF-ATTENUATED PROPHYLACTIC AND THERAPEUTIC VACCINES AGAINST PATHOGENS | October 2020 | April 2022 | Allow | 18 | 1 | 0 | No | No |
| 17072136 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE | October 2020 | May 2023 | Allow | 31 | 3 | 0 | Yes | No |
| 17043192 | Antigenic Peptides For Prevention And Treatment Of Cancer | September 2020 | November 2023 | Allow | 37 | 0 | 1 | Yes | No |
| 17027295 | Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor | September 2020 | July 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17025486 | AMH-INH-GNIH TRI-EXPRESSION GENE VACCINE OF IMPROVING FECUNDITY OF ANIMALS, PREPARATION METHOD AND APPLICATION | September 2020 | March 2022 | Allow | 18 | 1 | 0 | No | No |
| 17014028 | IMMUNOTHERAPEUTIC COMPOSITIONS | September 2020 | January 2023 | Abandon | 28 | 2 | 1 | No | No |
| 17004583 | RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS | August 2020 | January 2023 | Allow | 29 | 3 | 1 | Yes | No |
| 17003818 | METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | August 2020 | March 2022 | Allow | 19 | 1 | 0 | No | No |
| 17000377 | VACCINE COMPOSITION AND METHOD OF PREVENTING PORCINE EPIDEMIC DIARRHEA VIRUS INFECTION IN SWINE | August 2020 | May 2022 | Allow | 21 | 1 | 1 | Yes | No |
| 16997552 | COMBINATION THERAPY FOR TREATMENT OF BRAIN CANCERS | August 2020 | April 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16993856 | HA BINDING AGENTS | August 2020 | February 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 16947694 | TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS | August 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16969423 | IMMUNOGENIC COMPOSITION AND VACCINE FOR GENERATING AN IMMUNE RESPONSE TO NOROVIRUS | August 2020 | December 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16966726 | A NOVEL VACCINE ADJUVANT | July 2020 | May 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16937801 | COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSE | July 2020 | February 2022 | Allow | 19 | 1 | 0 | No | No |
| 16938707 | Half-life optimized linker composition | July 2020 | February 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 16937171 | COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSE | July 2020 | February 2022 | Allow | 19 | 1 | 0 | No | No |
| 16935813 | COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSE | July 2020 | February 2022 | Allow | 18 | 1 | 0 | No | No |
| 16963718 | BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE | July 2020 | February 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 16927086 | ZIKA VIRUS PURIFICATION | July 2020 | July 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16926704 | RAPID AND PROLONGED IMMUNOGIC THERAPEUTIC | July 2020 | January 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 16926703 | RAPID AND PROLONGED IMMUNOGIC THERAPEUTIC | July 2020 | April 2021 | Allow | 9 | 2 | 0 | Yes | No |
| 16960869 | IMMUNE MODULATION | July 2020 | May 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16921959 | Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis | July 2020 | December 2021 | Allow | 17 | 2 | 0 | No | No |
| 16921113 | DIAGNOSTIC AND TREATMENT FOR COVID-19 | July 2020 | April 2022 | Allow | 21 | 3 | 1 | Yes | No |
| 16917899 | ALPHAHERPESVIRUS GLYCOPROTEIN D-ENCODING NUCLEIC ACID CONSTRUCTS AND METHODS | June 2020 | May 2021 | Allow | 11 | 2 | 0 | Yes | No |
| 16912886 | HIV Binding Agents | June 2020 | June 2022 | Abandon | 23 | 1 | 0 | Yes | No |
| 16911171 | MODIFIED VIRAL VECTORS AND METHODS OF MAKING AND USING THE SAME | June 2020 | May 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16954835 | VACCINES WITH ENHANCED IMMUNOGENICITY, LOW ALLERGENICITY AND REACTOGENICITY | June 2020 | October 2021 | Allow | 16 | 1 | 1 | No | No |
| 16902068 | CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE | June 2020 | September 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16900070 | NOVEL ADJUVANT FOR ANIMAL AND HUMAN VACCINES | June 2020 | May 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16772194 | HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS | June 2020 | August 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16896574 | METHOD AND SYSTEM FOR INACTIVATING VIRUS INFECTIVITY FOR PRODUCING LIVE-ATTENUATED VACCINES | June 2020 | March 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16768844 | VECTOR FOR THE PRODUCTION OF AAV PARTICLES | June 2020 | February 2023 | Allow | 33 | 1 | 0 | No | No |
| 16768489 | IMMUNO-MODULATED REPLICATION-EFFICIENT VACCINIA VIRUS STRAIN | May 2020 | December 2022 | Allow | 30 | 1 | 0 | No | No |
| 16768057 | SYNPIII, A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL PIGMENT EPITHELIUM | May 2020 | October 2022 | Allow | 29 | 1 | 0 | No | No |
| 16764541 | PASYLATED VEGFR/PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY | May 2020 | September 2022 | Allow | 28 | 1 | 0 | No | No |
| 16874431 | DUAL-MOLECULAR DNA VACCINE COMPOSED OF A VIRAL ANTIGEN AND AN IMMUNE COSTIMULATOR | May 2020 | May 2022 | Abandon | 24 | 0 | 1 | No | No |
| 15930966 | IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | May 2020 | May 2023 | Allow | 36 | 1 | 1 | No | No |
| 16870874 | METHODS, SYSTEMS, AND DEVICES FOR MEASURING IMMUNITY TO SARS-COV-2 | May 2020 | October 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16867750 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | May 2020 | October 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16868243 | NON-NEUROINVASIVE VIRUSES AND USES THEREOF | May 2020 | May 2022 | Allow | 24 | 1 | 1 | No | No |
| 16868246 | Non-Neuroinvasive Viruses and Uses Thereof | May 2020 | February 2022 | Allow | 21 | 1 | 0 | No | No |
| 16861758 | REPLICATION-DEFECTIVE ARENAVIRUS VECTORS | April 2020 | March 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16759584 | TAU PEPTIDE IMMUNOGEN CONSTRUCTS | April 2020 | February 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16855115 | APOPTOTIC UPREGULATION BY MYXOMA VIRUS EXPRESSING WALLEYE DERMAL SARCOMA VIRUS ORFC | April 2020 | January 2023 | Allow | 33 | 1 | 1 | No | No |
| 16854703 | SINGLE-DOMAIN VHH ANTIBODIES DIRECTED TO NOROVIRUS GI.1 AND GII.4 AND THEIR USE | April 2020 | January 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16843439 | COMPOSITIONS AND METHODS FOR STABILIZING ALPHAVIRUSES WITH IMPROVED FORMULATIONS | April 2020 | May 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16840760 | VIRUS PURIFICATION | April 2020 | March 2022 | Allow | 24 | 1 | 0 | No | No |
| 16836515 | Improved Compositions And Methods For Viral Delivery Of Neoepitopes And Uses Thereof | March 2020 | April 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16830461 | METHODS OF PREVENTING SECONDARY INFECTIONS | March 2020 | March 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16648475 | MOLECULAR GRAFTING OF COMPLEX, BROADLY NEUTRALIZING ANTIBODY EPITOPES | March 2020 | March 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16648439 | SYNTHETIC HEMAGGLUTININ AS UNIVERSAL VACCINE AGAINST INFECTION BY TYPE B INFLUENZA VIRUSES (IBV) | March 2020 | May 2022 | Allow | 26 | 3 | 0 | Yes | No |
| 16822354 | COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSE | March 2020 | March 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16816320 | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue | March 2020 | December 2022 | Allow | 33 | 1 | 0 | No | No |
| 16645646 | METHODS AND COMPOSITIONS TO ENHANCE THE IMMUNOGENICITY OF TUMORS | March 2020 | June 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16645020 | Combination Therapies of Hepatitis B Virus (HBV)-infected individuals using Parapoxvirus Ovis (PPVO) and at Least one Further Antiviral Drug | March 2020 | February 2024 | Abandon | 47 | 3 | 1 | Yes | No |
| 16808701 | METHODS AND COMPOSITIONS FOR TREATING GLIOMA AND MEDULLOBLASTOMA BRAIN TUMORS USING THE ZIKA VIRUS | March 2020 | January 2022 | Allow | 22 | 1 | 0 | No | No |
| 16799090 | MODIFIED ONCOLYTIC VIRUS | February 2020 | November 2021 | Allow | 20 | 2 | 0 | Yes | No |
| 16641236 | Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Antibody | February 2020 | October 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16795433 | MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF | February 2020 | August 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16790841 | COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT AAV | February 2020 | March 2023 | Allow | 37 | 1 | 1 | No | No |
| 16790114 | REOVIRUSES HAVING MODIFIED SEQUENCES | February 2020 | December 2021 | Allow | 22 | 1 | 1 | No | No |
| 16786134 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | February 2020 | February 2023 | Allow | 36 | 2 | 0 | Yes | No |
| 16782268 | POXVIRAL VACCINES | February 2020 | November 2021 | Allow | 21 | 1 | 1 | No | No |
| 16747433 | SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY | January 2020 | April 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16740203 | ONCOLYTIC VIRUS STRAIN | January 2020 | October 2021 | Allow | 21 | 2 | 1 | Yes | No |
| 16736327 | MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOF | January 2020 | August 2021 | Allow | 19 | 1 | 0 | No | No |
| 16727561 | NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODY | December 2019 | December 2021 | Allow | 24 | 1 | 1 | No | No |
| 16626281 | CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES | December 2019 | November 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16717946 | HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE | December 2019 | July 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16704669 | USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR | December 2019 | November 2021 | Allow | 23 | 1 | 0 | No | No |
| 16702764 | VIRUS PURIFICATION | December 2019 | August 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16617889 | A METHOD TO CREATE PERSONALIZED CANINE CANCER VACCINES | November 2019 | May 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16662096 | NOVEL IMMUNIZATION AGENTS AND METHODS OF USE | October 2019 | June 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16604343 | A METHOD FOR PREDICTING TIME-TO-VIRAL CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION UNDER DIRECT ACTING ANTIVIRAL (DAA) THERAPY | October 2019 | March 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16593658 | COMPOSITIONS AND METHODS FOR INDUCING PROTECTIVE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION | October 2019 | August 2021 | Allow | 23 | 1 | 0 | Yes | No |
| 16551787 | BACULOVIRUS-BASED PRODUCTION OF BIOPHARMACEUTICALS FREE OF CONTAMINATING BACULOVIRAL VIRIONS | August 2019 | September 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16547059 | PHAGE COMPOSITION AND USE THEREOF IN INACTIVING ANTIBIOTIC RESISTANCE PATHOGENIC BACTERIA | August 2019 | July 2022 | Abandon | 35 | 2 | 0 | Yes | No |
| 16546749 | COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID | August 2019 | May 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16547051 | PHAGE AND USE THEREOF IN SOIL REMEDIATION | August 2019 | October 2021 | Allow | 26 | 2 | 1 | Yes | No |
| 16538664 | METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDS | August 2019 | August 2021 | Allow | 24 | 1 | 0 | No | No |
| 16530786 | COMPOSITIONS, METHODS AND USES FOR IMPROVED HUMAN PAPILLOMA VIRUS CONSTRUCTS | August 2019 | July 2021 | Allow | 23 | 1 | 0 | Yes | No |
| 16522371 | METHODS AND COMPOSITIONS RELATING TO VIRAL LATENCY | July 2019 | February 2021 | Allow | 19 | 0 | 0 | Yes | No |
| 16520467 | COMPOSITIONS AND METHODS FOR DETECTING HUMAN PAPILLOMAVIRUS NUCLEIC ACID | July 2019 | March 2021 | Allow | 20 | 1 | 0 | No | No |
| 16505168 | PURIFICATION OF HERPES VIRUS | July 2019 | September 2021 | Allow | 26 | 2 | 0 | Yes | No |
| 16452783 | INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE | June 2019 | September 2021 | Allow | 27 | 2 | 0 | Yes | No |
| 16447209 | RECOMBINANT B11 BACTERIOPHAGES AND USES THEREOF | June 2019 | September 2020 | Allow | 15 | 0 | 0 | Yes | No |
| 16439604 | RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | June 2019 | September 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16431769 | ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAME | June 2019 | September 2020 | Allow | 15 | 0 | 0 | No | No |
| 16423839 | METHODS AND COMPOSITIONS TO INCREASE IMMUNE RESPONSE TO VACCINES | May 2019 | April 2021 | Allow | 23 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, BAO Q.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LI, BAO Q works in Art Unit 1648 and has examined 805 patent applications in our dataset. With an allowance rate of 59.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner LI, BAO Q's allowance rate of 59.6% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LI, BAO Q receive 1.99 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LI, BAO Q is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by LI, BAO Q. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.1% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 46.3% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 127.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 85.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 78.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.3% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.